Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Integra Lifesciences Holdings (IART) EPS (Basic) (2016 - 2026)

Integra Lifesciences Holdings' EPS (Basic) history spans 17 years, with the latest figure at -$0.02 for Q4 2025.

  • On a quarterly basis, EPS (Basic) fell 108.0% to -$0.02 in Q4 2025 year-over-year; TTM through Dec 2025 was -$6.73, a 7377.78% decrease, with the full-year FY2025 number at -$6.74, down 7388.89% from a year prior.
  • EPS (Basic) hit -$0.02 in Q4 2025 for Integra Lifesciences Holdings, up from -$0.07 in the prior quarter.
  • Over the last five years, EPS (Basic) for IART hit a ceiling of $0.64 in Q4 2022 and a floor of -$6.31 in Q2 2025.
  • Historically, EPS (Basic) has averaged -$0.09 across 5 years, with a median of $0.26 in 2023.
  • Biggest five-year swings in EPS (Basic): soared 9511.78% in 2021 and later plummeted 3843.75% in 2025.
  • Tracing IART's EPS (Basic) over 5 years: stood at $0.54 in 2021, then grew by 18.52% to $0.64 in 2022, then plummeted by 59.38% to $0.26 in 2023, then decreased by 3.85% to $0.25 in 2024, then tumbled by 108.0% to -$0.02 in 2025.
  • Business Quant data shows EPS (Basic) for IART at -$0.02 in Q4 2025, -$0.07 in Q3 2025, and -$6.31 in Q2 2025.